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Background and purpose   Sclerostin is produced by osteocytes 
and is an inhibitor of bone formation. Thus, inhibition of scleros-
tin by a monoclonal antibody increases bone formation and 
improves fracture repair. Sclerostin expression is upregulated in 
unloaded bone and is downregulated by loading. We wanted to 
determine whether an anti-sclerostin antibody would stimulate 
metaphyseal healing in unloaded bone in a rat model. 
Methods   10-week-old male rats (n = 48) were divided into 
4 groups, with 12 in each. In 24 rats, the right hind limb was 
unloaded by paralyzing the calf and thigh muscles with an injec-
tion of botulinum toxin A (Botox). 3 days later, all the animals had 
a steel screw inserted into the right proximal tibia. Starting 3 days 
after screw insertion, either anti-sclerostin antibody (Scl-Ab) or 
saline was given twice weekly. The other 24 rats did not receive 
Botox injections and they were treated with Scl-Ab or saline to 
serve as normal-loaded controls. Screw pull-out force was mea-
sured 4 weeks after insertion, as an indicator of the regenerative 
response of bone to trauma.
Results   Unloading reduced the pull-out force. Scl-Ab treat-
ment increased the pull-out force, with or without unloading. The 
response to the antibody was similar in both groups, and no statis-
tically significant relationship was found between unloading and 
antibody treatment. The cancellous bone at a distance from the 
screw showed changes in bone volume fraction that followed the 
same pattern as the pull-out force.
Interpretation   Scl-Ab increases bone formation and screw 
fixation to a similar degree in loaded and unloaded bone.  

The secreted glycoprotein sclerostin is the product of the SOST 
gene. Sclerostin is an important negative regulator of bone, and 
naturally occurring mutations of the SOST gene in humans 
lead to the high bone mass condition sclerostosis (Balemans 
et al. 2001, Brunkow et al. 2001). This high bone mass pheno-
type is also present in animal models of SOST deficiency (Li et 
al. 2008). Sclerostin asserts its function, in part, by inhibiting 
canonical Wnt signaling (Li et al. 2005). This is important for 
osteoblast differentiation (Galli et al. 2010) and also for bone 
healing and regeneration (Chen et al. 2007, Kim et al. 2007). 
The SOST gene is expressed almost exclusively in osteocytes 
(Poole et al. 2005), and sclerostin expression is thought to be a 
means for osteocytes to locally regulate bone formation (Galli 
et al. 2010). Sclerostin appears to be vital for the bone to be 
able to respond to mechanical loading (Robling et al. 2008), 
and lack of sclerostin prevents osteopenia due to unloading 
(Lin et al. 2009). One therapeutic option has been to block 
sclerostin with an antibody. Such treatment has increased bone 
mass in animal models of postmenopausal osteoporosis (Li et 
al. 2009) or disuse-induced bone loss (Tian et al. 2011), and in 
gonad-intact aged male rats and non-human primates (Li et al. 
2010, Ominsky et al. 2010). Furthermore, fracture healing has 
been found to be improved in rodents and non-human primates 
treated with an anti-sclerostin antibody (Agholme et al. 2010, 
Ominsky et al. 2011). 
We have previously shown that inhibition of sclerostin 
improves bone regeneration and implant fixation during 
normal loading conditions (Agholme et al. 2010). However, 
in contrast to laboratory animals, many patients do not bear 
weight on fractured limbs for a long time. It is therefore 
important to determine the effect of sclerostin inhibition on 
bone healing under unloaded conditions.
Paralysis of hind limb muscles using botulinum toxin A 
(Botox) causes rapid bone loss due to reduced weight bearing 
(Chappard et al. 2001, Warner et al. 2006). We examined the 
effect of sclerostin inhibition on metaphyseal bone healing in 
a rat model with Botox injections. Fully weight-bearing ani-
mals were included as controls. 
Materials and methods
Forty-eight 10-week-old male Sprague-Dawley rats (Taconic, 
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g were used. To unload the bone, 24 animals were injected 
with Botox (Allergan, Irvine, CA) in the extensor muscles of 
the right hind leg 3 days before surgery. All animals had a 
stainless steel screw inserted unilaterally in the right proximal 
tibia (Agholme et al. 2010). After surgery, the rats were ran-
domly divided into 4 groups of 12 animals. One Botox-treated 
(unloaded) group and one untreated (loaded) group received 
subcutaneous injections of 25 mg/kg Scl-Ab twice weekly 
for 4 weeks, with injections starting 3 days after surgery. The 
other 2 groups were injected with saline solution at the same 
time points. The rats were killed 4 weeks after surgery. 
Implants
Stainless steel (316L) screws (thread M 1.7) were used. 
The threaded part of the screw is 2.8 mm long. The screws 
were custom-made and fitted with a head that enabled it to 
be mounted in a materials testing machine. The head has a 
3.3-mm long portion that protrudes into the subcutaneous 
space. This type of screw has been used in this model previ-
ously (Agholme et al. 2010).
Antibody
An anti-sclerostin monoclonal antibody (Scl-AbVI) specifi-
cally designed for rat studies was provided by Amgen Inc. 
(Thousand Oaks, CA).
Botox injection
In animals allocated to Botox treatment, the right hind limb 
was shaved and cleaned with chlorhexidine alcohol. The rats 
were anesthetized with isoflurane and using an insulin syringe, 
they were given 5 × 1 U of Botox intramuscularly in the calf 
and quadriceps femoris muscles. 2 days after injection, none 
of the injected animals were using the injected limb. After 2 
weeks, the injection procedure was repeated to ensure that the 
effect of the Botox did not recede. 
Surgical procedure
The rats were anesthetized with isoflurane and operated under 
sterile conditions. Each rat received 7 mg oxytetracycline and 
0.015 mg buprenorphine at the time of surgery. The right hind 
limb was shaved and cleaned with chlorhexidine alcohol. The 
rat was placed in a sterile surgical glove and the shaved leg 
was pulled out through a hole in the glove. Sterile tape was 
wrapped around the paw, and the leg was cleaned once more 
with chlorhexidine alcohol. The medial proximal metaphysis 
was exposed with a longitudinal incision. The periosteum was 
reflected proximally up to the epiphysis. An insertion hole 
was hand-drilled in the cancellous bone, approximately 3 mm 
distal to the physis, using a regular 1.2-mm injection needle. 
A screw was inserted in the hole and screwed in place. The 
skin was sutured using a 4/0-monofilament nylon suture. The 
animals were allowed to bear full weight immediately after 
waking from anesthesia. They received 0.007 mg buprenor-
phine as postoperative analgesic every 12 h for 48 h. The rats 
were given free access to food and water during the experi-
ment, and were housed 3 per cage at 21°C in a room with a 
cycle of 12 h light and 12 h dark. The study was approved by 
the Regional Ethics Committee for Animal Experiments and 
we followed institutional guidelines for care and treatment of 
laboratory animals. 
Mechanical evaluation
The rats were killed using carbon dioxide at the designated 
time point. Harvested bones were kept moist by saline irriga-
tion and all bones were tested within 1 h of harvesting. All 
screws were tested for pull-out strength in a computerized 
materials testing machine (100 R; DDL Inc.), at a cross-head 
speed of 0.1 mm/s. The machine recorded the maximum force 
and the energy uptake until the force had dropped to 90% of 
maximum. The stiffness was then decided by the operator as 
the slope of the linear portion of the force/distance curve. The 
peak pull-out force was considered the primary variable. All 
analyses were performed while being blinded for treatment. 
3 animals were excluded, 2 due to surgical mistakes and 1 
because the tibia fractured at the screw during harvesting. All 
exclusions were done under blind conditions. The 3 animals 
that were excluded belonged to Botox-treated groups. 
Micro-CT (µCT) 
After pull-out testing, the right proximal tibia of all animals 
was scanned using μCT (Skyscan 1172 v. 1.5; Skyscan, Aar-
teselar, Belgium). Figure 1 shows the region of interest ana-
lyzed. The μCT scanner acquired topographic images of the 
bone with an isotropic voxel size of 15 μm at energy settings 
of 100 kV and 100 μA, using aluminum filter of 0.5 mm and 10 
repeated scans. The images were reconstructed using NRecon 
Figure 1. Region of interest used for µCT analysis. Frontal and trans-
verse sections of the proximal tibia (epiphysis removed) from saline-
treated (A) and Scl-Ab-treated (B) weight-bearing animals. A 1.5-mm 
long region in the metaphysis was chosen (dashed lines). In this region, 
only the trabecular bone was evaluated (white trace). This region was 
situated away from the screw (*) so that it would not be influenced by 
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(Skyscan v. 1.5.1.4; Aarteselar), by correcting for ring arti-
facts and beam hardening. Analysis of bone volume fraction 
(BV/TV, when measured by μCT) and trabecular thickness, 
separation, and number (Tb.Th, Tb.Sp, Tb.N) were performed 
in CTAn (Skyscan v. 1.9.1.0; Aarteselar). BV/TV was con-
sidered the primary variable. All analyses were performed in 
a blinded manner. 4 additional samples had to be excluded 
since the μCT measurement region (specified in Figure 1) was 
too damaged to be properly evaluated. These exclusions were 
done while blinded. All animals that were excluded belonged 
to the Botox-treated groups. 
Statistics 
Results are presented as mean (SD). Comparisons for group 
mean differences were calculated for treatment effects on log-
transformed data, if variances were unequal—as decided by 
Levene’s test. Differences were tested using 2-way ANOVA 
with Scl-Ab and Botox treatment as fixed factors, and t-test 
for post hoc comparisons. A result was considered to be sta-
tistically significant at p-values < 0.05. All statistical analyses 
were performed using SPSS v. 18.0.
Results
The mean body weight of all groups increased during the 
experiment, but Botox-injected rats grew less. They weighted 
22 (6) g less than uninjected rats at the time of surgery, and 75 
(11) g less at the end of the experiment. The latter weight dif-
ference cannot be explained only by a reduced muscle mass in 
the treated hind limbs (data not shown). 
Implant fixation
2-way ANOVA confirmed an effect of both Scl-Ab and 
unloading on pull-out force (p < 0.001 for both), but we did 
not find any statistically significant interaction between them. 
Thus, the response to the antibody appeared to be similar in 
loaded and unloaded bone. 
Unloading reduced the pull-out force by 56% compared to 
the controls with weight bearing (p < 0.001) (Figure 2). In 
unloaded bone, Scl-Ab treatment increased the pull-out force 
by 62% (p = 0.01) with corresponding increases in energy 
and stiffness (Figure 2). Antibody treatment did not restore 
the pull-out force (p = 0.05) or energy (p < 0.001) to values 
corresponding to those for weight-bearing controls. In weight-
bearing bone, Scl-Ab treatment almost doubled the pull-out 
force (p = 0.003) and increased pull-out energy and stiffness 
(Figure 2).
µCT analysis
2-way ANOVA confirmed an effect of both Scl-Ab (p = 0.029) 
and unloading (p < 0.001) on BV/TV (Figure 3). Both fac-
tors also influenced trabecular thickness (p < 0.001 for both). 
Unloading, but not antibody treatment, influenced trabecular 
number and trabecular spacing (p < 0.001 for both). How-
ever, there was no statistically significant interaction between 
unloading and antibody treatment for BV/TV or other mor-
phometric parameters. 
In unloaded controls, there was a 90% decrease in cancel-
lous BV/TV compared to weight-bearing controls (p < 0.001). 
This decrease in BV/TV was primarily due to a profound 
decrease in trabecular number (p < 0.001). Trabecular thick-
ness also decreased (p < 0.001), while trabecular spacing 
increased (p < 0.001). 
Figure 2. Effect of treatment with anti-sclerostin antibody (Scl-Ab) on screw fixation. A. Peak pull-out force. 
B. Pull-out energy. C. Stiffness. Compared to controls, Scl-Ab treatment significantly increased peak force 
(a: p = 0.01; b: p < 0.001) and energy (c: p = 0.02; d: p < 0.001) both with and without loading. Stiffness was 
significantly increased in an unloaded setting (e: p = 0.03). Unloading had a large effect on screw fixation, 
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Scl-Ab treatment of the unloaded bone increased BV/TV 
by 80% (p = 0.03). There was a 25% increase in trabecular 
thickness (p < 0.001) with no statistically significant change in 
trabecular number or spacing. In weight-bearing bone, Scl-Ab 
treatment caused a 20% increase in trabecular thickness 
(p < 0.001). There was no statistically significant increase in 
cancellous BV/TV (Figure 3), trabecular number, or spacing. 
Discussion
The quality of fixation of the implant may be considered to be 
the end result of a fracture-healing response of the kind that 
is prominent in cancellous bone. As in any stable metaphyseal 
fracture, this healing response leads to direct bone formation 
around the screw. This new bone is shaped like a thread, grasp-
ing the screw. The strength of this new bone, which reflects 
the fracture healing response, directly influences the force 
that will be needed to pull out the screw. We have previously 
shown that an increase in pull-out force using anti-sclerostin 
antibody is related to an increase in the amount of mineralized 
bone surrounding the screw (Agholme et al. 2010). 
In the present study, Scl-Ab improved the fixation of a steel 
screw in the trabecular bone of normal-loaded and unloaded 
young male rats. Paralysis of muscles of the hind limb leads to 
rapid loss of bone mineral content and to changes in trabecular 
structure (Chappard et al. 2001, Warner et al. 2006). In this 
degraded bone, the Scl-Ab treatment had a positive effect. The 
raw data suggests that there was a greater response in loaded 
bone (Figure 2). However, for a correct statistical analysis, one 
requires log-transformation to equalize variation, and to com-
pare the percentage changes rather than absolute differences. 
When this was performed, the interaction between loading 
and antibody disappeared. 
Scl-Ab treatment increased BV/TV in the unloaded bone. 
These findings are consistent with a previous study in which 
administration of anti-sclerostin antibody prevented bone deg-
radation after immobilization of the hind limb using bandages 
(Tian et al. 2011). In that study, Scl-Ab was shown to increase 
bone formation and reduce bone resorption in unloaded 
bone. In our study, the region of evaluation for μCT analysis 
included the primary spongiosa. This is different from other 
studies with Scl-Ab (Li et al. 2009, Tian et al. 2011), where 
the primary spongiosa was excluded. Nevertheless, Scl-Ab 
treatment induced an increase in trabecular thickness in both 
loaded and unloaded bone, with minimal effects on trabecular 
separation and number. This result is similar to that in a previ-
ous report on loaded bone (Agholme et al. 2010).
The expression of sclerostin is highly upregulated by 
unloading (Robling et al. 2008) and mice lacking sclerostin 
expression are insensitive to unloading (Lin et al. 2009). We 
had therefore expected a proportionately stronger response 
to the antibody treatment in unloaded bone. However, even 
with a high level of sclerostin inhibition, we could not fully 
counter the effects of unloading. This could have been due 
to very strong expression of sclerostin in the unloaded bone, 
in comparison to normally-loaded bone, in which case the 
amount of antibody administered may have been inadequate 
to fully inhibit sclerostin. It is also possible that sclerostin 
is not the only mechanically responsive modulator of bone 
during unloading. Expression of Dickkopf-1 (Dkk1), another 
Wnt inhibitor, is also upregulated during unloading. However, 
we recently showed that blocking of Dkk1 had no effect on 
pull-out strength parameters in unloaded bone despite the 
increase in pull-out strength parameters in normally-loaded 
bone (Agholme et al. 2011). 
The present study had several limitations. We chose to only 
investigate the initial stages of fracture healing at a single 
Figure 3. Effect of anti-sclerostin antibody (Scl-Ab) on trabecular bone volume in the proximal tibia, as measured by µCT. A. Bone volume fraction. 
B. Trabecular number. C. Trabecular Thickness. D. Trabecular separation. Botox treatment significantly reduced BV/TV, Tb.N, and Tb.Th compared 
to loaded controls (p < 0.001). Antibody treatment increased BV/TV both in the loaded and unloaded tibia, but only the increase in the unloaded 
tibia was significant (a: p = 0.03). Trabecular thickness was also significantly increased, however (b, c: p < 0.001). 632  Acta Orthopaedica 2011; 82 (5): 628–632
time point. The study was designed to determine the effects 
of antibody treatment, with possible therapeutic applications 
in mind. To understand the physiological aspects, it would be 
more appropriate to study RNA and protein expression under 
different loading conditions. In addition, μCT evaluation in a 
region including the primary spongiosa might not reflect con-
ditions in which growth plates are closed. 
In summary, we found that the large anabolic effect of Scl-Ab 
on traumatized bone in young male rats can also be found in 
unloaded bone. Sclerostin inhibition could be a valuable thera-
peutic option in settings where the bone is unloaded. How-
ever, we were unable to find an interaction between Scl-Ab 
treatment and loading, suggesting that although sclerostin is 
expressed in the bone that is forming in response to metaphy-
seal trauma, this expression is not more sensitive to unloading 
than expression anywhere else. 
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